Revelation Biosciences (NASDAQ:REVB – Get Free Report) and Viking Therapeutics (NASDAQ:VKTX – Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.
Risk & Volatility
Revelation Biosciences has a beta of -0.11, indicating that its stock price is 111% less volatile than the S&P 500. Comparatively, Viking Therapeutics has a beta of 0.65, indicating that its stock price is 35% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Revelation Biosciences and Viking Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Revelation Biosciences | 1 | 0 | 0 | 0 | 1.00 |
| Viking Therapeutics | 1 | 3 | 9 | 3 | 2.88 |
Institutional & Insider Ownership
12.8% of Revelation Biosciences shares are owned by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are owned by institutional investors. 14.2% of Revelation Biosciences shares are owned by insiders. Comparatively, 4.1% of Viking Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Profitability
This table compares Revelation Biosciences and Viking Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Revelation Biosciences | N/A | -145.03% | -112.72% |
| Viking Therapeutics | N/A | -29.35% | -28.41% |
Valuation & Earnings
This table compares Revelation Biosciences and Viking Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Revelation Biosciences | N/A | N/A | -$15.04 million | ($30.05) | -0.03 |
| Viking Therapeutics | N/A | N/A | -$109.96 million | ($2.12) | -16.66 |
Viking Therapeutics is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks.
Summary
Viking Therapeutics beats Revelation Biosciences on 9 of the 12 factors compared between the two stocks.
About Revelation Biosciences
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.
About Viking Therapeutics
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Receive News & Ratings for Revelation Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revelation Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
